Akari Therapeutics, Plc

US$7.37As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AKTXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (49.94%)
Div yield —
ROE (140.09%)
Biotechnology
Beta (5Y) 1.47
PE TTM —
TSR TTM (75.43%)
Mkt cap US$16.84M
ROIC (36.82%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$7.60
3.14%
(75.07%)
Hold 7|3|7|10|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.09
0.09
0.10
0.10
8.07%
4.98%
12.64%
12.73%
Revenue$M
1.924
2.032
2.100
2.139
8.50%
9.69%
11.84%
17.02%
Peers (US$16.84M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.670
0.053
0.058
EBIT/Intx
0.522
0.069
0.069
Own earn%
(5.16)
255.01
205.96
Sh yield%
32.52
9.51
7.48
Owners
Insiders/Inst%
14.72
86.97
Short interest%
4.24
SBC / revenue%
4.28
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
16
Op margin range%
19–27
$1 testx
—
Incr. ROIC%
2